Rezvani wins American Cancer Society grant

Hutch News

Rezvani wins American Cancer Society grant

The $583,000 four-year research award will aid research using monoclonal antibodies to lower the chances of non-Hodgkin lymphoma relapse, complications

May 14, 2012
Dr. Andrew Rezvani

Dr. Andrew Rezvani, Clinical Research Division

Photo by Dean Forbes

The Clinical Research Division's Dr. Andrew Rezvani has received a four-year, $583,000 mentored research scholar grant from the American Cancer Society. The award supports his work in improving outcomes for patients who receive blood and bone marrow transplants to treat non-Hodgkin lymphoma.

"We are studying ways to integrate the monoclonal antibody rituximab into the transplant process in order to reduce the risk of lymphoma relapse," said Rezvani, a member of the Storb Lab. "We are also studying whether rituximab might help prevent graft-vs.-host disease, a major complication of blood and bone marrow transplantation. Ultimately, we hope that the funded research will lead to more effective treatments and cures for people with non-Hodgkin lymphoma."

The American Cancer Society, the largest non-government, nonprofit funding source of cancer research in the U.S., has awarded 135 national research and training grants totaling $51,965,000 to investigators at 93 institutions nationwide in one of two grants cycles for 2012. All the grants go into effect July 1.

[Adapted from an American Cancer Society news release]

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.